×
Supernus Pharmaceuticals EBITDA 2011-2024 | SUPN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Supernus Pharmaceuticals ebitda from 2011 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Supernus Pharmaceuticals EBITDA 2011-2024 | SUPN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Supernus Pharmaceuticals ebitda from 2011 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Teva Pharmaceutical Industries (TEVA)
$20.1B
Dr Reddy's Laboratories (RDY)
$13.1B
BridgeBio Pharma (BBIO)
$5B
Bausch Health Cos (BHC)
$3B
Amphastar Pharmaceuticals (AMPH)
$2.4B
Taysha Gene Therapies (TSHA)
$449M
Personalis (PSNL)
$315M
Assembly Biosciences (ASMB)
$117M
Acasti Pharma (ACST)
$28M
Sol-Gel Technologies (SLGL)
$20M
Evoke Pharma (EVOK)
$4M
Teligent (TLGT)
$0M